Trial Profile
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2022
Price :
$35
*
At a glance
- Drugs NP-001 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Neuraltus Pharmaceuticals
- 01 Dec 2022 According to a Neuvivo media release, results from this study were presented in the journal Biomedicines.
- 01 Dec 2022 Results published in the Media Release
- 02 Jun 2022 According to Neuvivo media release, results were presented at the ENCALS Conference (European Network to Cure ALS).